NCT01586663

Brief Summary

This is a randomized controlled trial with blinded evaluator and follow-up of one year. Seventy six patients with diffuse systemic sclerosis, will be randomized into two groups.The patients can not change their medication during the study. Patients will be evaluated at baseline and at 3, 6, 9 and 12 months. The experimental group will use a serial night time position splint who will be adjusted monthly, while the control group will remain the drug treatment. The outcomes assessed will be: pain, hand range of motion, quality of life, functional capacity, upper limb function and dexterity. Our hypothesis is that the serial night time position splint will improve the hand range of motion in diffuse systemic sclerosis patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
76

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jan 2010

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

April 25, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 27, 2012

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

May 1, 2012

Status Verified

April 1, 2012

Enrollment Period

2.9 years

First QC Date

April 25, 2012

Last Update Submit

April 27, 2012

Conditions

Keywords

Diffuse Systemic SclerosisHandRange of motionSplint

Outcome Measures

Primary Outcomes (1)

  • Change in hand range of motion

    Measured by goniometry

    Baseline and after 3, 6, 9 and 12 months

Secondary Outcomes (5)

  • Change in pain

    Baseline, after 10, 20 and 40 weeks

  • Change in functional capacity

    Baseline, after 10, 20 and 40 weeks

  • Change in quality of life

    Basline, after 10, 20 and 40 weeks

  • Change in upper limb function

    Baseline, after 10, 20 and 40 weeks

  • Change in dexterity

    Baseline, after 3, 6, 9 and 12 months

Study Arms (2)

Experimental Group

EXPERIMENTAL

Splint group

Device: Serial night time position splint

Control Group

ACTIVE COMPARATOR

Drug treatment

Drug: Drug treatment

Interventions

This group will use a serial night time position splint, adjusted monthly, during three months.

Experimental Group

This patients will keep there drug treatment and will receive their splints on the end of the study.

Control Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diffuse Systemic scleroses diagnosed following the ACR criteria
  • Older than 18 years old
  • Sclerodactyly

You may not qualify if:

  • Neurological, psychiatric diseases and other rheumatic disease (including overlapping)
  • Previous use of splints or allergy to splint material
  • Surgery schedule to the next 12 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidade Federal de Sao Paulo

São Paulo, São Paulo, 04023-062, Brazil

RECRUITING

MeSH Terms

Conditions

Scleroderma, Diffuse

Condition Hierarchy (Ancestors)

Scleroderma, SystemicConnective Tissue DiseasesSkin and Connective Tissue DiseasesSkin Diseases

Study Officials

  • Jamil Natour, PhD

    Federal University of São Paulo

    STUDY CHAIR

Central Study Contacts

Fernanda P Cardoso, OT

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 25, 2012

First Posted

April 27, 2012

Study Start

January 1, 2010

Primary Completion

December 1, 2012

Study Completion

December 1, 2012

Last Updated

May 1, 2012

Record last verified: 2012-04

Locations